2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MD скачать в хорошем качестве

2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MD

In 2020, Lynparza (olaparib) and Rubraca (rucaparib), two chemotherapy like drugs that come in pill form, were FDA approved for the treatment of advanced prostate cancer in men with a BRCA mutation (they may also be useful in men with other mutations, e.g. ATM). Men with BRCA mutations are more likely to get prostate cancer and more likely to have aggressive types of prostate cancer; however, the discovery and confirmation that these medications are effective in about 50% of these men has given us another line of defense to treat them. 0:06 What is a PARP inhibitor and how are they used to treat prostate cancer? 1:54 For men with a BRCA mutation, can (or should) PARP inhibitors be used as a substitute for cytotoxic chemotherapy like Taxotere or hormone therapy? 2:33 Are PARP inhibitors useful in men without a BRCA mutation? Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors. The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs. #ProstateCancer #Prostate #MarkScholzMD